{"DataElement":{"publicId":"4889143","version":"1","preferredName":"Patient Glioblastoma Anaplastic Astrocytoma Gliosarcoma Glioma   Fibrillary Astrocytoma Histologic Confirmation Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"A yes or no or NA coded response indicating whether a patient with DIPG meets the criteria for enrollment into a clinical trial by having a histologically confirmed diagnosis of glioblastoma, anaplastic astrocytoma, gliocarcoma, glioma or fibrillary astrocytoma.","longName":"4886933v1.0:3506036v1.0","context":"PBTC","contextVersion":"1","DataElementConcept":{"publicId":"4886933","version":"1","preferredName":"Patient Glioblastoma Anaplastic Astrocytoma Gliosarcoma Glioma   Fibrillary Astrocytoma Histologic Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The most malignant astrocytic tumor (WHO grade IV).  Composed of poorly differentiated neoplastic astrocytes.  It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history, without evidence of a less malignant precursor lesion (primary glioblastoma). _A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma._A type of glioma (cancer of the brain that comes from glial, or supportive, cells)._A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells)._The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes.   The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO).__Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4886931v1.0","context":"PBTC","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4889111","version":"1","preferredName":"Glioblastoma Anaplastic Astrocytoma Gliosarcoma Glioma Fibrillary Astrocytoma Histologic Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO):A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO):A type of glioma (cancer of the brain that comes from glial, or supportive, cells).:A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.:The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO):Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissu","longName":"4889111v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Gliosarcoma","conceptCode":"C3796","definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Glioma","conceptCode":"C3059","definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Fibrillary Astrocytoma","conceptCode":"C4322","definition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19BE28E4-948E-AD70-E050-BB89AD435672","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"RICHARDS","dateCreated":"2015-06-30","modifiedBy":"ONEDATA","dateModified":"2015-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19357ED3-AE35-93B7-E050-BB89AD43370C","latestVersionIndicator":"Yes","beginDate":"2015-06-23","endDate":null,"createdBy":"RICHARDS","dateCreated":"2015-06-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"curated for eligibility checklist","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"For patients with DIPG who ha","type":"Preferred Question Text","description":"For patients with DIPG who have undergone biopsy, does the patient have a histologically confirmed diagnosis of glioblastoma, anaplastic astrocytoma, gliosarcoma, glioma or diffuse fibrillary (WHO grade II) astrocytoma?","url":null,"context":"PBTC"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"If the patient has atypical DIPG findings on MRI, does the patient have a histologically confirmed diagnosis of a WHO Grade II-IV glioma?","url":null,"context":"PBTC"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Does the patient have DIPG with atypical presentation on MRI which has been confirmed by biopsy as malignant glioma WHO II-IV?","url":null,"context":"PBTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19BE28E4-965D-AD70-E050-BB89AD435672","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"RICHARDS","dateCreated":"2015-06-30","modifiedBy":"RICHARDS","dateModified":"2017-04-26","changeDescription":"PBTC sr 063015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}